Biological and Clinical Activity of Tivozanib, a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4 Week on, 2 Week off Schedule in Patients With Advanced Solid Tumors.

Authors: Eskens FALM, de Jonge MJA, Bhargava P, Isoe T, Cotreau MM, Esteves B, Hayashi K, Burger H, Thomeer M, van Doorn L, Verweij J. Clin Cancer Res. 10.1158/1078-0432.CCR-11-0411. (October 5, 2011). Click here for link to article.